Travere Therapeutics Presents Knowledge Reinforcing Scientific Advantage of FILSPARI ® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 By Investing.com
Practically 60% of sufferers with IgAN within the SPARTAN Research achieved full…
